Protein Kinase C (19-31)

Protein Kinase C (19-31), a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), is used as protein kinase C substrate peptide for testing the protein kinase C activity[1][2].

Product Specifications

CAS Number

[121545-65-1]

Product Name Alternative

PKC (19-31)

UNSPSC

12352209

Target

PKC

Type

Peptides

Related Pathways

Epigenetics; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/protein-kinase-c-19-31.html

Purity

99.74

Solubility

H2O : ≥ 50 mg/mL

Smiles

CC(C)[C@@H](C(O)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCN)NC([C@H](CCC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](C)NC(CNC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](C)NC([C@@H](NC([C@@H](N)CCCNC(N)=N)=O)CC1=CC=CC=C1)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C67H118N26O16

Molecular Weight

1543.82

References & Citations

[1]Mellor H, et al. The extended protein kinase C superfamily. Biochem J. 1998 Jun 1;332 (Pt 2) :281-92.|[2]Nishizuka Y (1995) . Protein kinase C and lipid signaling for sustained cellular responses" (abstract) . FASEB J. 9 (7) : 484–96.